Polycyclic compound as LRRK2 kinase inhibitor and preparation method and application thereof
By developing a polycyclic compound, the problem of difficulty in effectively inhibiting LRRK2 kinase in the prior art was solved, and the potential treatment and prevention of Parkinson's disease, inflammatory bowel disease and cancer were achieved, and excellent LRRK2 inhibitory activity was demonstrated.
Patent Information
- Application Number
- CN202310592800.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively develop leucine-rich repeat kinase 2 (LRRK2) inhibitors for the treatment of familial Parkinson's disease and related inflammatory diseases, cancer and neurodegenerative diseases.
A polycyclic compound is provided that, through specific structures and preparation methods, has efficient inhibition of LRRK2 kinase activity for the treatment and prevention of LRRK2-mediated diseases such as Parkinson's disease, inflammatory bowel disease and cancer.
The compound showed excellent LRRK2 inhibitory activity, with potential therapeutic and prevention effects in Parkinson's disease, inflammatory bowel disease and cancer, providing a new drug target.
Smart Images

Figure CN119019402A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of medicine, and specifically relates to a polycyclic compound as an LRRK2 kinase inhibitor and its preparation method and use, for example, in the treatment and prevention of LRRK2-mediated inflammatory diseases, cancer and neurodegenerative diseases (such as Parkinson's disease and Alzheimer's disease). Background Art
[0002] Leucine-rich repeat kinase 2 (LRRK2) is the most common mutated gene in familial Parkinson's disease (PD). LRRK2 gene mutations are also associated with primary PD, so LRRK2 kinase inhibitors may be an effective therapeutic drug for PD. In addition, LRRK2 mutations are also associated with immune-related diseases, such as inflammatory bowel disease (IBD), and are also potential targets for the treatment of such diseases.
[0003] In summary, there is an urgent need in the art to develop a new class of leucine-rich repeat kinase 2 (LRRK2) inhibitors. Summary of the invention
[0004] The purpose of the present invention is to provide a class of polycyclic compounds that effectively inhibit LRRK2, as well as a preparation method thereof and use thereof for treating and preventing LRRK2-mediated diseases such as inflammatory diseases, cancer and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease.
[0005] In the first aspect of the present invention, there is provided a compound as shown in general formula I, or various isomers and pharmaceutically acceptable salts thereof:
[0006]
[0007] Where:
[0008] Select from the following ring structures:
[0009] Selected from the following bicyclic structures:
[0010]
[0011] Among them: Among them:
[0012] X is selected from N or CR 5 ;
[0013] R 1 , R 2 , R 4 , R 5 and R 6 Each independently is optionally substituted by one or more (such as 1, 2, 3, 4 or 5) Rs1 The substituted group is selected from the group consisting of hydrogen, halogen, amino, cyano, SF5, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -C 0-6 Alkylene-OC 1-12 Alkyl (including C 1-12 Alkoxy), -C 1-12 Alkylthio (-SC 1-12 Alkyl), -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-4 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO2C 1-6 Alkyl, -C 0-6 Alkylene-SO2C 6-10 Aryl, -C 0-6 Alkylene-SO25 to 10 membered heteroaryl, -C 0-6 Alkylene-SO2C 3-6 Cycloalkyl, -C 1-13 Alkylene-OH (such as -C(C 1-6 Alkyl)2-OH), -C 3-12 Cycloalkylene-OH;
[0014] Each R s1 Independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, -SO2NR a R b 、-SO2C 1-6 Alkyl, -SO2C 3-6 Cycloalkyl, -SO2C 6-10 Aryl, -SO2-5 to 10 membered heteroaryl, -CONR a R b 、-CONRa-C 6-10 Aryl, -CONR a -5 to 10 membered heteroaryl, -COC 1-6 Alkyl, -COC 3-6 Cycloalkyl, -COC 6-10Aryl, -CO-5 to 10 membered heteroaryl, C 1-6 Alkoxy and oxo (=O) radical substitution;
[0015] R 3 is optionally replaced by one or more (e.g., 1, 2, 3, 4 or 5) R s2 The substituted group is selected from the group consisting of hydrogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -4 to 15 membered heterocyclic group, -C 0-6 Alkylene-OC 1-12 Alkyl (such as -C 1-12 Alkoxy), -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO2C 1-6 Alkyl, -C 0-6 Alkylene-SO2C 6-10 Aryl, -C 0-6 Alkylene-SO25 to 10 membered heteroaryl, -C 0-6 Alkylene-SO2C 3-6 Cycloalkyl, -C 1-13 Alkylene-OH (such as -C(C 1-6 Alkyl)2-OH)-C 3-12 Cycloalkylene-OH;
[0016] Each R s2 is independently optionally replaced by one or more (such as 1, 2, 3, 4 or 5) R c or R 3a The substituted group is selected from the group consisting of halogen, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, OC3-6 Cycloalkyl, amino, cyano, -SO2NR a R b 、-SO2R 8 、-CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a 5- to 10-membered heteroaryl, -C(O)R 8 and oxo (=O) groups; or, when two R s2 When located on adjacent atoms, they optionally together form a c The substituted ring is selected from the group consisting of: C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 Aryl and 5- to 10-membered heteroaryl;
[0017] R 3a is optionally replaced by one or more (e.g., 1, 2, 3, 4 or 5) R s3 The substituted group is selected from the group consisting of hydrogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -4 to 15 membered heterocyclic group, -C 0-6 Alkylene-OC 1-12 Alkyl (such as -C 1-12 Alkoxy), -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO2C 1-6 Alkyl, -C 0-6 Alkylene-SO2C 6-10 Aryl, -C 0-6 Alkylene-SO25 to 10 membered heteroaryl, -C 0-6 Alkylene-SO2C 3-6 Cycloalkyl, -C 1-12Alkylene-OH (such as -C(C 1-6 Alkyl)2-OH)-C 3-12 Cycloalkylene-OH;
[0018] Each R s3 Independently selected from the group consisting of halogen, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, OC 3-6 Cycloalkyl, amino, cyano, -SO2NR a R b 、-SO2R 8 (such as -SO2C 1-6 Alkyl, -SO2C 3-6 Cycloalkyl, -SO2C 6-10 Aryl, -SO2-5 to 10 membered heteroaryl), -CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a 5- to 10-membered heteroaryl, -C(O)R 8 (Preferably, -C(O)R 8 Selected from -COC 1-6 Alkyl, -COC 3-6 Cycloalkyl, -COC 6-10 aryl, -CO5 to 10 membered heteroaryl) and oxo (=O);
[0019] Or, when R 1 and R 2 , R 1 and R 3 or R 2 and R 3 When located on adjacent atoms, R 1 and R 2 , R 1 and R 3 or R 2 and R 3 optionally together form optionally one or more (such as 1, 2, 3, 4 or 5) R c The substituted ring is selected from the group consisting of: C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 Aryl and 5- to 10-membered heteroaryl;
[0020] R 7 Selected from the group consisting of hydrogen, C1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, NR a R b , OR a ;
[0021] R 8 is optionally replaced by one or more (e.g., 1, 2, 3, 4 or 5) R c The substituted group is selected from the following group: C 1-6 Alkyl, C 3-6 Cycloalkyl, C 6-10 Aryl, 5- to 10-membered heteroaryl;
[0022] R a and R b Independently selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, or R a and R b Together with the nitrogen atom to which they are attached, they optionally form a 3- to 6-membered heterocyclic ring wherein the heteroatoms are selected from N, O and S;
[0023] R c Each independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, -NH2, -CN, -NH(C 1-4 Alkyl), -N(C 1-4 Alkyl)2, -OH, -OC 1-6 Alkyl; or, when both R c When located on the same atom, they are optionally combined to form an unsubstituted or substituted with one or more (e.g., 1, 2, 3, 4 or 5) selected from halogen, -CN and C 1-4 The C substituted by the alkyl substituent 3-6 Cycloalkyl.
[0024] In another preferred embodiment, "R 1 , R 2 , R 4 , R 5 and R 6 Each is independently one or more R s1 The group substituted by "is selected from the following group" means "R 1 , R 2 , R 4 , R5 and R 6 Each alkyl, amino, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl in the optional groups defined in s1 replaced.
[0025] In another preferred embodiment, "R 3 is optionally represented by one or more R s2 The substituted group selected from the following group" refers to R 3 Each alkyl, alkylene, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl in the optional groups defined in s2 replaced.
[0026] In another preferred embodiment, "each R s2 are independently optionally replaced by one or more R c or R 3a The substituted group selected from the following group" refers to R s2 Each alkyl, alkylene, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl in the optional groups defined in c or R 3a replaced.
[0027] In another preferred embodiment, each R s2 are independently optionally replaced by one or more R c The substituted groups are as defined above.
[0028] In another preferred embodiment, R 8 Select from the following group: C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, C 6-10 Aryl, 5- to 10-membered heteroaryl.
[0029] In another preferred embodiment, -SO2R 8 is optionally represented by one or more R c The substituted group is selected from the following group: -SO2-C 1-6 Alkyl, -SO2-C 3-6 Cycloalkyl, -SO2-C 6-10 Aryl, -SO2-5 to 10 membered heteroaryl.
[0030] In another preferred embodiment, -COR 8 is optionally represented by one or more R c The substituted group is selected from the following group: -CO-C 1-6Alkyl, -CO-C 3-6 Cycloalkyl, -CO-C 6-10 Aryl, -CO-5 to 10 membered heteroaryl.
[0031] In another preferred embodiment, the compound is a compound represented by formula II:
[0032]
[0033] Where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 As defined in formula I. In another preferred embodiment, the compound is a compound represented by formula III:
[0034]
[0035] Where R 1 , R 2 , R 3 , R 4 , R 6 and R 7 As defined in Formula I.
[0036] In another preferred embodiment, the compound is a compound represented by formula IV:
[0037]
[0038] Where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 As defined in formula I. In another preferred embodiment, the compound is a compound represented by formula V:
[0039]
[0040] Where R 1 , R 2 , R 3 , R 4 , R 6 and R 7 As defined in Formula I.
[0041] In another preferred embodiment, the compound is a compound represented by formula VI:
[0042]
[0043] Where X is selected from N or CR 5 ;
[0044] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 As defined in Formula I.
[0045] In another preferred embodiment, the compound is a compound represented by formula VII:
[0046]
[0047] Where X is selected from N or CR 5 ;
[0048] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 As defined in Formula I.
[0049] In another preferred embodiment, the compound is a compound represented by formula VIII:
[0050]
[0051] Where X is selected from N or CR 5 ;
[0052] Y is selected from S, O, NR 2 ;
[0053] R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 As defined in Formula I.
[0054] In another preferred embodiment, the compound is a compound represented by formula IX:
[0055]
[0056] Where R 1 , R 2 , R 3 , R 4 , R 5 and R 7 As defined in Formula I.
[0057] In another preferred embodiment, R 1 is optionally represented by one or more R s1 The substituted group is selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl.
[0058] In another preferred embodiment, R 1 is optionally represented by one or more R s1 The substituted group is selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl; wherein each R s1 Independently selected from the group consisting of halogen, C 1-6 alkyl.
[0059] In another preferred embodiment, R 1 Selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl.
[0060] In another preferred embodiment, R 1 Selected from the following group: -C 1-12 Alkyl, C 3-10 Cycloalkyl.
[0061] In another preferred embodiment, R 1 Selected from the group consisting of methyl, ethyl, propyl, butyl, cyclopropyl, and cyclobutyl.
[0062] In another preferred embodiment, R 2 Selected from the group consisting of hydrogen, -C 1-12 alkyl.
[0063] In another preferred embodiment, R 2 For hydrogen.
[0064] In another preferred embodiment, R 2 is optionally represented by one or more R s1 The substituted group is selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl.
[0065] In another preferred embodiment, R 2 is optionally represented by one or more Rs1 The substituted group is selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl; wherein each R s1 Independently selected from the group consisting of halogen, C 1-6 alkyl.
[0066] In another preferred embodiment, R 2 Selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl.
[0067] In another preferred embodiment, R 2 Selected from the following group: -C 1-12 Alkyl, C 3-10 Cycloalkyl.
[0068] In another preferred embodiment, R 2 Selected from the group consisting of methyl, ethyl, propyl, butyl, cyclopropyl, and cyclobutyl.
[0069] In another preferred embodiment, R 1 Selected from the group consisting of hydrogen, -C 1-12 alkyl.
[0070] In another preferred embodiment, R 1 For hydrogen.
[0071] In another preferred embodiment, R 4 , R 5 and R 6 Each independently is one or more R s1 The substituted group is selected from the group consisting of hydrogen, halogen, -C 1-12 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl.
[0072] In another preferred embodiment, R 5 Selected from the group consisting of hydrogen, halogen, -C 1-12 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl.
[0073] In another preferred embodiment, R 5 Selected from the group consisting of hydrogen, halogen, -C 1-6 alkyl.
[0074] In another preferred embodiment, R 4 and R 6Each independently is one or more R s1 The substituted group is selected from the group consisting of hydrogen, halogen, -C 1-12 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl.
[0075] In another preferred embodiment, each R s1 Independently selected from the group consisting of halogen, C 1-6 alkyl.
[0076] In another preferred embodiment, R 7 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated ring. Alkyl.
[0077] In another preferred embodiment, R 7 Selected from the group consisting of hydrogen, C 1-6 alkyl.
[0078] In another preferred embodiment, R 3 is optionally represented by one or more R s2 The substituted group is selected from the group consisting of hydrogen, -C 1-12 alkyl, -3 to 15 membered heterocyclic group, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-SO2C 1-6 alkyl.
[0079] In another preferred embodiment, R 3 is optionally represented by one or more R s2 The substituted group is selected from the following group: C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group.
[0080] In another preferred embodiment, R 3 Select from the following group:
[0081] -C(C 1-6 Alkyl)2-R s2 ,
[0082] in,
[0083] Y 1 Selected from the group consisting of CH2, CHR s2 , C(Rs2 )2, O, S, SO, SO2, NH, NR s2 ;
[0084] n3 and n6 are each independently 0, 1, 2 or 3;
[0085] n1 and n2 are each independently 0, 1, 2 or 3, and n1 and n2 are not 0 or 3 at the same time;
[0086] n4 and n5 are each independently 0, 1 or 2, and n4 and n5 are not 0 at the same time.
[0087] n7 and n8 are each independently 1 or 2;
[0088] n9 and n10 are each independently 0 or 1;
[0089] R s2 As defined in Formula I.
[0090] In another preferred embodiment, Y 1 Selected from the group consisting of CH, CHR s2 , C(R s2 )2. O. S. NR a 、NC(O)R 8 、NSO2R 8 、NSO2NR a R b .
[0091] In another preferred embodiment, each R s2 Independently selected from the group consisting of halogen, hydroxyl, C 1-6 Alkyl, OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -OC 3-6 Cycloalkyl, amino, cyano, -SO2NR a R b 、-SO2R 8 -CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a -5 to 10 membered heteroaryl, -C(O)R 8 , C 1-6 Alkoxy and oxo (=O) groups are substituted.
[0092] In another preferred embodiment, Ring A and Ring B are each independently a corresponding group in the specific compounds shown in Table A or in the Preparation Examples.
[0093] In another preferred embodiment, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 Each is independently a corresponding group in a specific compound shown in Table A or in the Preparation Examples.
[0094] In another preferred embodiment, the general compound is selected from the following Table A
[0095] Table A
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112] In another preferred embodiment, the compounds (such as compounds represented by Formula I to Formula IX) include all stereoisomers.
[0113] In another preferred embodiment, the compounds (such as compounds of Formula I to Formula IX) include all atropisomers.
[0114] In another preferred embodiment, the stereoisomers of the compounds (such as compounds represented by Formula I to Formula IX) are cis-trans isomers.
[0115] In another preferred embodiment, the compounds (such as compounds represented by general formula I to general formula IX) are optically pure isomers.
[0116] In another preferred embodiment, the compound (such as the compounds shown in Formula I to Formula IX) is a racemate.
[0117] In another preferred embodiment, the compounds (such as compounds represented by general formula I to general formula IX) are enantiomers.
[0118] In another preferred embodiment, any one or more hydrogen atoms in the compounds (such as compounds represented by Formula I to Formula IX) may be replaced by deuterium atoms.
[0119] In another preferred embodiment, the compound (such as the compound shown in Formula I to Formula IX) includes a prodrug thereof.
[0120] In another preferred embodiment, the pharmaceutically acceptable salt of the compound (such as the compound shown in general formula I to general formula IX) is selected from the following group: hydrochloride, hydrobromide, sulfate, phosphate, methanesulfonate, trifluoromethanesulfonate, benzenesulfonate, p-toluenesulfonate (toluenesulfonate), 1-naphthalenesulfonate, 2-naphthalenesulfonate, acetate, trifluoroacetate, malate, tartrate, citrate, lactate, oxalate, succinate, fumarate, maleate, benzoate, salicylate, phenylacetate, mandelate.
[0121] In the second aspect of the present invention, a pharmaceutical composition is provided, which comprises (a) a safe and effective amount of the active ingredient of the compound as described in the first aspect or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, or a prodrug thereof, and (b) a pharmaceutically acceptable carrier or excipient.
[0122] In another preferred embodiment, the pharmaceutical composition further comprises another therapeutic agent.
[0123] In another preferred embodiment, the additional therapeutic agent is an immune checkpoint protein inhibitor.
[0124] In another preferred embodiment, the immune checkpoint protein inhibitor is an antibody.
[0125] In the third aspect of the present invention, there is provided a use of the compound as described in the first aspect or a pharmaceutically acceptable salt thereof, a stereoisomer thereof or a tautomer thereof, or a prodrug thereof, wherein the use is one or more uses selected from the following group:
[0126] (i) preparing LRRK2 inhibitors;
[0127] (ii) preparing a drug for treating or preventing a disease mediated by LRRK2;
[0128] (iii) preparing a medicament for treating or preventing Parkinson's disease and / or cancer;
[0129] (iv) preparing drugs for the treatment or prevention of cancer for use in combination with immune checkpoint protein inhibitors (such as antibodies);
[0130] (v) preparing drugs for treating or preventing inflammatory diseases, tumors and / or neurodegenerative diseases;
[0131] (vi) preparing a medicament for treating or preventing tumors (such as cancer) for use in combination with tumor drugs or therapies.
[0132] In another preferred embodiment, the inflammatory disease is inflammatory bowel disease (IBD).
[0133] In another preferred embodiment, the tumor is cancer.
[0134] In another preferred embodiment, the neurodegenerative disease is selected from the group consisting of Parkinson's disease and Alzheimer's disease.
[0135] In another preferred embodiment, the immune checkpoint protein inhibitor is an antibody.
[0136] In another preferred embodiment, the tumor drugs or therapies include: PD-1 antibodies, CTLA-4 antibodies, PD-L1 antibodies, PD-L2 antibodies, adoptive cell transplantation therapy, cancer vaccines, IDO (indoleamine 2,3-dioxygenase) inhibitors, TDO (tryptophan dioxygenase) inhibitors, IDO / TDO dual inhibitors, EP4 antagonists, HDAC (histone deacetylase) inhibitors, STING (interferon gene stimulator protein) activators, kinase inhibitors, any other chemotherapy drugs or targeted therapy drugs, radiotherapy drugs.
[0137] In another preferred embodiment, tumors (such as cancer), neurodegenerative diseases (such as Parkinson's disease, senile dementia, i.e. Alzheimer's disease), inflammatory diseases (such as inflammatory bowel disease (IBD)).
[0138] In another preferred embodiment, the LRRK2-mediated disease is selected from the group consisting of cancer, Parkinson's disease, Alzheimer's disease, inflammatory bowel disease (IBD), tuberculosis, leprosy, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, atopic dermatitis, rheumatoid arthritis, spondyloarthritis, gout, systemic lupus erythematosus, Sjögren's syndrome, scleroderma, antiphospholipid syndrome, vasculitis, osteoarthritis, nonalcoholic fatty liver hepatitis, autoimmune Hepatitis, autoimmune hepatobiliary diseases, primary sclerosing cholangitis, nephritis, celiac disease, autoimmune ITP, transplant rejection, ischemia-reperfusion injury of solid organs, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington's disease, allergic diseases, asthma, multiple sclerosis, type 2 diabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-1 converting enzyme-associated febrile syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated periodic syndrome, and periodontitis.
[0139] In a fourth aspect of the present invention, a pharmaceutical combination is provided, wherein the pharmaceutical composition comprises:
[0140] (a) a first active ingredient, wherein the first active ingredient is the compound according to the first aspect or a pharmaceutically acceptable salt thereof, a stereoisomer or a tautomer thereof, or a prodrug thereof; and
[0141] (b) a second active ingredient, wherein the second active ingredient is an immune checkpoint protein inhibitor.
[0142] In another preferred embodiment, the immune checkpoint protein inhibitor is an antibody.
[0143] In another preferred embodiment, the immune checkpoint protein inhibitor is selected from the following group: PD-1 antibody, CTLA-4 antibody, PD-L1 antibody, PD-L2 antibody, IDO (indoleamine 2,3-dioxygenase) inhibitor, TDO (tryptophan dioxygenase) inhibitor, IDO / TDO dual inhibitor, EP4 antagonist, HDAC (histone deacetylase) inhibitor, STING (interferon gene stimulator) activator, kinase inhibitor.
[0144] In the fifth aspect of the present invention, a method for inhibiting the activity of LRRK2 kinase is provided, comprising the steps of contacting LRRK2 kinase with the compound as described in the first aspect or its pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof, thereby inhibiting the activity of LRRK2 kinase.
[0145] In another preferred embodiment, the method is non-therapeutic in vitro.
[0146] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION
[0147] After extensive and in-depth research, the inventors unexpectedly discovered that a class of compounds with novel structures (such as compounds shown in Formula I) have excellent leucine-rich repeat kinase 2 (LRRK2) inhibitory activity. Based on this, the inventors have completed the present invention.
[0148] definition
[0149] As used herein, the term "alkyl", as a whole or as part of a group, refers to a monovalent saturated aliphatic hydrocarbon group having the specified number of carbon atoms, for example, C 1-12 (C 1-6 ) Alkyl refers to a monovalent saturated aliphatic hydrocarbon group having 1 to 12 (1 to 6) carbon atoms, the term including straight chain and branched hydrocarbon groups. In this context, preferred alkyl groups have 1 to 6 carbon atoms (i.e., C 1-6 Alkyl), more preferably alkyl has 1 to 4 carbon atoms (i.e. C 1-4 Examples of alkyl groups include, but are not limited to, methyl (i.e., CH3-), ethyl (i.e., CH3CH2-), n-propyl (i.e., CH3CH2CH2-), isopropyl (i.e., (CH3)2CH-), n-butyl (i.e., CH3CH2CH2CH2-), isobutyl (i.e., (CH3)2CHCH2-), sec-butyl (i.e., (CH3)(CH3CH2)CH-), tert-butyl (i.e., (CH3)3C-), n-pentyl (i.e., CH3CH2CH2CH2CH2-), and neopentyl (i.e., (CH3)3CCH2-).
[0150] As used herein, the term "aryl", as a whole or as part of a group, refers to a aryl radical having a specified number of carbon atoms, such as 6 to 20 carbon atoms. 6-20 Aryl (preferably 6-14 C 6-14 Aryl, preferably 6-10 C 6-10 The term "aromatic" refers to a monovalent aromatic carbocyclic group having a carbon atom as a ring atom, which may be a monocyclic ring (such as phenyl) or a condensed ring (such as naphthyl or anthracenyl). When the aryl is a condensed ring, as long as the connection point is located on the aromatic carbon atom, the other rings in the condensed ring may be non-aromatic. Examples of such condensed rings include 2-benzoxazolone, 2H-1,4-benzoxazine-3(4H)-one-7-yl, etc. Preferred aryl groups include phenyl and naphthyl.
[0151] As used herein, the term "alkenyl", as a whole or as part of a group, refers to an unsaturated hydrocarbon group having a specified number of carbon atoms and having at least 1 (e.g., 1 to 2) unsaturated olefinic bonds (>C=C<). Generally, an alkenyl group has 2-12 carbon atoms, i.e., C 2-12 Preferably, the alkenyl group has 2 to 6 carbon atoms, i.e., C 2-6 More preferably, the alkenyl group has 2 to 4 carbon atoms, i.e., C 2-4 Examples of such groups include, for example, vinyl, allyl, but-3-enyl. Similarly, the term "alkynyl" refers to an unsaturated hydrocarbon group having a specified number of carbon atoms and having at least one (e.g., 1 or 2) unsaturated carbon-carbon triple bonds. Typically, an alkynyl group has 2-12 carbon atoms, i.e., C 2-12 Alkynyl, preferably, alkynyl has 2-6 carbon atoms, i.e., C 2-6 More preferably, the alkynyl group has 2 to 4 carbon atoms, i.e., C 2-4 Examples of such groups include, for example, ethynyl, 1- and 3-propynyl, 3-butynyl.
[0152] As used herein, the term "cycloalkyl", as a whole or as part of a group, refers to a cyclic alkyl group (preferably, a saturated cyclic alkyl group) having a monocyclic or polycyclic ring system (including fused systems, bridged ring systems and spiro ring systems) with a specified number of carbon ring atoms. When the cycloalkylalkyl group is a fused ring system, as long as the point of attachment is through the cycloalkyl ring, the other one or more rings fused may be cycloalkyl, heterocyclic, aryl or heteroaryl. Preferably, the cycloalkyl group has 3-10 ring carbon atoms, i.e., C 3-10 More preferably, the cycloalkyl group has 3 to 6 ring carbon atoms, i.e., C 3-6 Cycloalkyl. Examples of suitable cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclooctyl.
[0153] As used herein, the term "halogen" refers to fluorine, chlorine, bromine and iodine. The term "halo" refers to one or more or all of the hydrogen in the group being replaced by halogen atoms (such as F, Cl, Br and I). For example, in this article, the term "haloalkyl" refers to an alkyl defined herein that is substituted by one or more halogen atoms, and examples of haloalkyl include, for example, -CF3, -CH2CF3.
[0154] As used herein, the term "heteroaryl", as a whole or as part of a group, refers to an aromatic group having a specified number of ring atoms and having 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur. Generally, heteroaryl refers to an aromatic group having 1 to 10 carbon atoms and 1 to 4 heteroatoms in the ring. Preferably, the heteroaryl has 5 to 10 ring atoms (i.e., 5 to 10 heteroaryl groups), more preferably, the heteroaryl has 5 to 6 ring atoms (i.e., 5 to 6 heteroaryl groups or 5 or 6 heteroaryl groups), and contains 1, 2, 3 or 4 heteroatoms. In this article, such heteroaryl can be monocyclic (such as pyridyl or furanyl) or fused ring (such as indolizinyl or benzothienyl). When the heteroaryl is a fused ring, as long as the point of attachment is through an atom of an aromatic heteroaryl (which can be a heteroatom in the ring such as N or a carbon atom), the fused another one or more rings can also be non-aromatic and / or contain a heteroatom ring. In some embodiments, the ring atom nitrogen and / or sulfur of the heteroaryl group is optionally oxidized to N-oxide (NO), sulfinyl or sulfonyl.Preferably, examples of heteroaryl groups include pyridyl, pyrrolyl, indolyl, thienyl and furanyl.
[0155] As used herein, the term "substituted heteroaryl" refers to a heteroaryl group substituted with 1 to 5, preferably 1 to 3, more preferably 1 to 2 substituents selected from the same substituents as defined for substituted aryl.
[0156] As used herein, as a whole or as part of a group, the term "heterocyclyl" (also referred to herein as "heterocycle" or "heterocyclic" or "heterocycloalkyl") refers to a saturated, partially saturated or unsaturated cyclic group (but not aromatic) having a specified number of ring atoms and containing 1 to 5 (such as 1, 2, 3 or 4, preferably 1 or 2) heteroatoms selected from nitrogen, sulfur or oxygen on the ring. The heterocyclyl can have a single ring system or a fused ring system (including bridged ring systems and spirocyclic systems). Generally, the ring of the heterocyclyl has 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from nitrogen, sulfur or oxygen. When the heterocyclyl is a fused ring system, as long as the point of attachment is through a non-aromatic ring, the fused one or more rings can be cycloalkyl, aryl or heteroaryl. The heterocyclyl can be connected to the rest of the compound through a carbon atom on the ring or a heteroatom on the ring (such as a nitrogen atom). In some embodiments, the nitrogen atom and / or sulfur atom of the heterocyclic group is optionally oxidized to provide N-oxide, sulfinyl and sulfonyl moieties. Preferably, the heterocyclic group includes 3 to 10 ring atoms (i.e., 3 to 10 membered heterocyclic groups), more preferably, includes 4 to 6 ring atoms (i.e., 4 to 6 membered heterocyclic groups), and contains 1, 2, 3 or 4 heterocyclic atoms.
[0157] As used herein, the term "substituted heterocyclic" or "substituted heterocycloalkyl" or "substituted heterocyclyl" refers to a heterocyclic group substituted with 1 to 5 (e.g., 1 to 3) substituents, the substituents being the same as those defined for substituted cycloalkyl.
[0158] In some embodiments, the above terms (such as "alkyl", "cycloalkyl", "heterocyclyl", "aryl", "heteroaryl", etc.) will include substituted and unsubstituted forms of the specified groups. Preferably, when substituted, substitution refers to 1 to 5 (such as 1 to 3, or 1 or 2) substituents as defined herein.
[0159] As used herein, the term "one or more" is preferably 1, 2, 3, 4 or 5, more preferably 1, 2 or 3.
[0160] Unless otherwise specified, herein, each cycloalkyl group is C 3-6 Cycloalkyl, each heterocyclic group is a 3- to 10-membered heterocyclic group, each aryl is a C 6-10 Aryl, each heteroaryl is a 5- to 10-membered heteroaryl.
[0161] In some embodiments, substituents for groups such as "alkyl", "cycloalkyl", "heterocyclyl", "aryl", "heteroaryl", etc. are selected from, but not limited to, the following chemical groups: halogen, -C 1-6 Alkyl, -C 3-8 Cycloalkyl, -C 1-6 Haloalkyl, -C 3-8 Halogenated cycloalkyl, -C 1-6 Alkoxy, -C 3-8 Cycloalkoxy, -C 1-6 Alkylthio, -C 0-6 Alkylene-OH, nitro, aldehyde, -SF5, -C 0-6 Alkylene-NR a R b , -C 0-6 Alkylene-carboxyl, -C 0-6 Alkylene-COR a , -C 0-6 Alkylene-CO2R a , -C 0-6 Alkylene-CONR d R e , -C 0-6 Alkylene-SO2R a , -C 0-6 Alkylene-SO2NR d R e , carbonyl, -C 0-6 Alkylene -CN, -C 3-8 Cycloalkyl-OH, -C2-6 Alkenyl, C 2-6 Alkynyl, -C 0-6 Alkylene-S(O)(NH)C 1-6 alkyl, -C 0-6 Alkylene-S(O)(NCN)C 1- 6alkyl, -C 0-6 Alkylene-NR c S(O)2R b , -C 0-6 Alkylene-NR c S(O)2NR c R b , -C 0-6 Alkylene-NR c C(O)NH2、-C 0-6 Alkylene-NR c C(O)R b , -C 0-6 Alkylene-NR c C(O)NR d R e , -C 0-6 Alkylene-NR c C(O)OR b , -C 0-6 Alkylene-NRSO2R b C(O)-R b , -C 0-6 Alkylene-P(O)R c R b , -C 0-6 Alkylene-P(O)(OR c )(OR b ),-C 0-6 Alkylene-C(O)C 1-6 Alkyleneamino, C 1-6 Heteroalkyl, C 3-10 Carbocyclic ring, C 5-10 aryl (ring), 4 to 10 membered heteroyl (ring), 5 to 10 membered heteroaryl (ring). a , R b and R c are independently hydrogen, unsubstituted C 1-8 Alkyl, unsubstituted heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted C 1-8 Alkyl, C 1-8 Alkoxy or C 1-8 Thioalkoxy, or unsubstituted aryl-C 1-4 alkyl.
[0162] As used herein, C 0-6Alkylene means that there is no alkylene or a C 1-6 Alkylene, i.e. C 0-6 Alkylene represents the absence (single bond) or C 1-6 Alkylene.
[0163] For compounds provided herein, bonds from substituents (typically R groups) to the center of a ring (such as heterocyclyl, cycloalkyl, aryl, and heteroaryl) will be understood to mean bonds providing attachment at any available vertex of the ring. As used herein, the terms "comprising," "including," or "comprising" indicate that various ingredients can be used together in a mixture or composition of the present invention. Thus, the terms "consisting essentially of" and "consisting of" are encompassed by the term "comprising."
[0164] As used herein, the term "stereoisomer" refers to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers.
[0165] As used herein, the term "tautomer" refers to alternative forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or tautomeric forms of a heteroaryl group comprising a ring atom attached to the -NH- portion of the ring and the =N- portion of the ring, such as pyrazole, imidazole, benzimidazole, triazole, and tetrazole.
[0166] Compounds of the present invention
[0167] As used herein, the term "compound of the present invention" refers to the compound described in the first aspect of the present invention, such as the compound shown in Formula I to IX. The term also includes various crystalline forms, various isomers, pharmaceutically acceptable salts, hydrates or solvates or prodrugs of the compound of the present invention.
[0168] As used herein, the term "pharmaceutically acceptable salt" refers to a non-toxic acid or alkaline earth metal salt of a compound of the present invention, such as a compound of Formula I to Formula IX. These salts can be prepared in situ during the final isolation and purification of the compounds of Formula I to Formula IX, or by reacting a suitable organic or inorganic acid or base with a basic or acidic functional group, respectively. Representative salts include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, gluconate heptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthylsulfonate, oxalate, pamoate, pectinate, thiocyanate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, and undecanoate. In addition, nitrogen-containing basic groups can be quaternized by the following reagents: alkyl halides, such as methyl, ethyl, propyl, butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides such as benzyl and phenethyl bromides, etc. Water-soluble or oil-soluble or dispersible products are obtained. Examples of acids that can be used to form pharmaceutically acceptable acid addition salts include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, and organic acids such as oxalic acid, maleic acid, methanesulfonic acid, succinic acid, and citric acid. Base addition salts can be prepared in situ during the final isolation and purification of the compounds of Formula I to Formula IX, or by reacting the carboxylic acid moiety with a suitable base (e.g., a pharmaceutically acceptable metal cation hydroxide, carbonate or bicarbonate) or ammonia, or an organic primary, secondary or tertiary amine, respectively. Pharmaceutically acceptable salts include, but are not limited to, alkali metal and alkaline earth metal cations, such as sodium, lithium, potassium, calcium, magnesium, aluminum salts, and the like, as well as non-toxic ammonium, quaternary ammonium and amine cations, including, but not limited to: ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Other representative organic amines for forming base addition salts include diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like.
[0169] As used herein, the term "solvate" refers to a complex formed by the coordination of the compound of the present invention with solvent molecules in a specific ratio. "Hydrate" refers to a complex formed by the coordination of the compound of the present invention with water.
[0170] As used herein, "prodrug" refers to any derivative of a compound of the invention that, when administered to a subject, is capable of providing, directly or indirectly, a compound of the invention or its active metabolite or residue. Particularly preferred derivatives and prodrugs are those that, when administered to a subject, increase the bioavailability of the compound of the invention (e.g., an orally administered compound is more readily absorbed into the blood) or increase the delivery of the parent compound to biological compartments (e.g., the brain or lymphatic system) relative to the parent species. Prodrugs include ester forms of the compounds of the invention.
[0171] When the compounds of the present invention exist as stereoisomers, the present invention includes all stereoisomers of the compounds.
[0172] When the compounds of the present invention exist as tautomers, the present invention includes all tautomers of the compounds.
[0173] In the case where the compounds of the present invention exist as tautomers, the present invention includes all atropisomers of the compounds.
[0174] The present invention also includes deuterated compounds produced by replacing any one or more hydrogen atoms in the compounds with its stable isotope deuterium.
[0175] Pharmaceutical compositions and methods of administration
[0176] Since the compounds of the present invention have excellent inhibitory activity against leucine-rich repeat kinase 2 (LRRK2), the compounds of the present invention and their various crystal forms, various isomers, pharmaceutically acceptable salts, hydrates or solvates or prodrugs, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredients can be used to treat, prevent and alleviate diseases mediated by protein kinase LRRK2. According to the prior art, the compounds of the present invention can be used for treatment, prevention and alleviation. According to the prior art, the compounds of the present invention can be used to treat the following diseases: degenerative diseases (including Parkinson's disease), inflammatory diseases (such as IBD) and tumors (such as cancer), or LRRK2-mediated diseases described in other parts of this article.
[0177] The present invention also provides active ingredients within the safe and effective amount range of the compounds of general formula I to general formula IX, and pharmaceutically acceptable carriers.
[0178] The "active ingredient" described in the present invention refers to the compounds of Formula I to Formula IX described in the present invention.
[0179] The "active ingredients" and pharmaceutical compositions of the present invention can be used as treatments for neurodegenerative diseases (including Parkinson's disease) and cancer.
[0180] "Safe and effective amount" means: the amount of active ingredient is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of active ingredient per dose, more preferably, 10-200 mg of active ingredient per dose. Preferably, the "one dose" is one tablet or capsule.
[0181] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the active ingredients of the present invention and with each other without significantly reducing the efficacy of the active ingredients.
[0182] Typically, the compounds of the preferred embodiments will be administered in a therapeutically effective amount by any acceptable mode of administration of a medicament having a similar effect. The actual dosage of the compounds (i.e., active ingredients) of the preferred embodiments is determined according to a number of factors, such as the severity of the disease to be treated, the age and relative health of the patient, the efficacy of the compound used, the route and form of administration, and other factors. The drug can be administered multiple times a day, preferably once or twice a day. All of these factors are within the consideration of the attending physician.
[0183] Purpose of preferred embodiments: The therapeutically effective dose can generally be a total daily dose for a patient administered once or in divided doses, for example, about 0.001 to about 1000 mg / kg body weight per day, preferably about 1.0 to about 30 mg / kg body weight per day. The unit dose composition may contain its dosage factor to form a daily dose. The choice of dosage form depends on various factors, such as the mode of administration and the bioavailability of the drug substance. Generally, the compounds of the preferred embodiments can be administered as pharmaceutical compositions by any of the following routes: oral, systemic administration (such as transdermal, intranasal or by suppository), or parenteral administration (such as intramuscular, intravenous or subcutaneous). The preferred mode of administration is oral, and a convenient daily dose can be adjusted according to the degree of bitterness. The composition can take the form of tablets, pills, capsules, semisolids, powders, sustained-release preparations, solutions, suspensions, elixirs, aerosols or any other suitable composition. Another preferred mode of administering the preferred embodiment compound is inhalation. This is an effective method for delivering therapeutic agents directly to the respiratory tract (see, e.g., U.S. Pat. No. 5,607,915).
[0184] Suitable pharmaceutically acceptable carriers or excipients include: such as treating agents and drug delivery modifiers and promoters, such as calcium phosphate, magnesium stearate, talc, monosaccharides, disaccharides, starch, gelatin, cellulose, sodium methylcellulose, carboxymethylcellulose, glucose, hydroxypropyl-B-cyclodextrin, polyvinylpyrrolidone, low melting point wax, ion exchange resins, etc., and any combination of two or more thereof. Liquid and semisolid excipients can be selected from glycerol, propylene glycol, water, ethanol and various oils, including petroleum, animal oil, vegetable oil or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers, particularly carriers for injectable solutions, include water, saline, aqueous glucose solutions and ethylene glycol. Other suitable pharmaceutically acceptable excipients are described in Remington's Pharmaceutical Sciences, Mack Pub. Co., New Jersey (1991), which is incorporated herein by reference.
[0185] Preparation method of the compound of the present invention
[0186] The compounds of the present invention can be prepared, separated or obtained by any method obvious to those skilled in the art. The compounds of the present invention can also be prepared according to the exemplary preparation schemes provided below (such as the methods in the examples). The reaction conditions, steps and reactants not provided in the exemplary preparation schemes are obvious and known to those skilled in the art. As used herein, the symbols and conventions used in these processes, schemes and examples, whether or not specific abbreviations are specifically defined, have meanings well known to those skilled in the art.
[0187] For example, the compounds of the present invention can be synthesized from known or commercially available raw materials according to Schemes 1, 2 or 3 shown below.
[0188]
[0189] In scheme 1, 2,4-dichloropyrrolo[2,1-f][1,2,4]triazine is used as the raw material, reduced with sodium borohydride, and then oxidized with DDQ to obtain intermediate Ⅰ-1. Then, it is coupled with a suitably substituted aminopyrazole by Buchwald coupling to obtain intermediate Ⅰ-2, followed by trifluoromethylation with reagents such as CF3SO2Na, and finally chlorinated with NCS to obtain the target product Ⅰ-4. In each formula, R 1 , R 2 and R 3 As defined elsewhere herein.
[0190]
[0191] In scheme 2, Ⅰ-1 is used as a raw material for bromination to obtain intermediate Ⅱ-2, and then different substituents are introduced by Suzuki or Still coupling according to the reagents used, followed by Buchwald coupling with a suitably substituted aminopyrazole to obtain intermediate Ⅱ-4. Then chlorination is performed to obtain the final product Ⅱ-5. In each formula, R 1 , R 2 , R 3 and R 4 As defined elsewhere in this document
[0192]
[0193] Ⅲ-1 is oxidized with a peroxide such as mCPBA to obtain Ⅲ-2, and then reacted with a suitably substituted aminopyrazole under the catalysis of p-toluenesulfonic acid monohydrate to obtain Ⅲ-3. After removing the protecting group, condensation with a suitable carboxylic acid is performed to obtain Ⅲ-5, and then cyclization to Ⅲ-6 is catalyzed by POCl3. Ⅲ-6 is then brominated and coupled to obtain the product Ⅲ-8. In each formula, R 1 , R 2 , R 3 , R 4 and R 5 As defined elsewhere herein.
[0194] Uses Also provided herein are uses of the compounds of the present invention, such as compounds of Formula I to Formula IX, for:
[0195] (i) preparing LRRK2 inhibitors for treating neurodegenerative diseases, inflammatory diseases (such as IBD) and cancer; and / or
[0196] (ii) preparing a drug for preventing and / or treating LRRK2-mediated diseases, especially Parkinson's disease; and / or
[0197] (iii) Preparation of combination drugs for tumor treatment including LRRK2 inhibitors and other tumor drugs: PD-1 antibody, CTLA-4 antibody, PD-L1 antibody, PD-L2 antibody, adoptive cell transplantation therapy, cancer vaccine, IDO (indoleamine 2,3-dioxygenase) inhibitor, TDO (tryptophan dioxygenase) inhibitor, IDO / TDO dual inhibitor, EP4 antagonist, HDAC (histone deacetylase) inhibitor, STING (interferon gene stimulator) activator, kinase inhibitor, any other chemotherapy drug or targeted therapy drug, radiotherapy drug.
[0198] The main advantages of the present invention include:
[0199] (a) The compounds of the present invention have excellent ability to inhibit LRRK2 activity.
[0200] Abbreviations and test conditions:
[0201] Unless otherwise specified, the abbreviations used in the examples of the present invention have the conventional meanings understood by those skilled in the art. For example, the following abbreviations have the following meanings: EA: ethyl acetate; DCM: dichloromethane; DIEA: diisopropylethylamine; NaBH4: sodium borohydride; DMF: N,N-dimethylformamide; DMSO: dimethyl sulfoxide; DPPF: 1,1'-bis(diphenylphosphino)ferrocene; DIAD: diisopropyl azodicarboxylate; EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; HATU: O-(7-nitrobenzotriazole)-1,1,3,3 -Tetramethyluronium hexafluorophosphate; HOAT: N-hydroxy-7-azobenzotriazole; IPA: isopropanol; LDA: lithium diisopropylamide; LiHMDS: lithium bis(hexamethyldisilazide)amide; NCS: N-chlorosuccinimide; NBS: N-bromosuccinimide; NIS: N-iodosuccinimide; PE: petroleum ether; EA: triethylamine; TFA: trifluoroacetic acid; THF: tetrahydrofuran; PPh3: triphenylphosphine; RT: room temperature; DDQ: 2,3-dichloro-5,6-dicyanobenzoquinone; ±BINAP: ±-1,1'-binaphthyl-2,2'-bis(diphenylphosphine).
[0202] Reverse phase HPLC purification conditions: Waters micromass ZQ 4000 (MAA050 model) was used as the mass detector, Waters 2487UV was used as the detector, and HPLC-MS analysis was performed on a Waters HPLC 2790. The chromatographic column used was Fenome OOB-4605-E0 (5U-XB-C18-100A, 50×4.6 mm). The mobile phase was eluent A (water, 0.05% TFA) and eluent B (CH3CN, 0.05% TFA), and the elution rate was 1 ml / min. The initial condition was 90% A for 1 minute, then 90% A linearly decreased to 10% A within 5 minutes, and then rose from 10% A to 90% A within 1 minute, and the total running time was 7 minutes. According to the properties of the compound, the mobile phase gradient and running time can be adjusted appropriately.
[0203] Chiral HPLC separation conditions: Agilent Technologies 1200 Infinity liquid chromatography system was used, and the chiral columns used were Daicel CHIRALPAK IG (Cat. No.: IG00EE-AT002), CHIRALPAK IG (Cat. No.: IG00CE-AQ017), and CHIRALPAK AD-H (Cat. No.: ADH0CE-EL100). The mobile phases were eluent A (n-hexane) and eluent B (ethanol), the elution rate was 0.8 or 3 ml / min, and the elution condition used a constant proportion of ethanol. Depending on the properties of the compound, the type of chiral column, the proportion of ethanol in the mobile phase, and the running time can be adjusted appropriately.
[0204] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are all calculated by weight, and the unit is weight parts.
[0205] Unless otherwise stated, the materials and reagents used in the examples of the present invention are commercially available products.
[0206] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
[0207] Example 1: T-1
[0208] 2-Methyl-2-(3-methyl-4-(pyrrolo[2,1-f][1,2,4]triazin-2-ylamino)-1H-pyrazol-1-yl)propionitrile
[0209]
[0210] Step 1: Preparation of M-1
[0211] 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine (4 g) was dissolved in ultra-dry THF (60 ml) and iPrOH (10 ml), and then NaBH4 (1287 mg) was added. After stirring at room temperature for 6 h, the mixture was filtered and dried. The resulting solid was dissolved in DCM (70 ml), and then DDQ (5796 mg) was added. After stirring at room temperature for 2 h, the mixture was quenched with a saturated solution of NaHCO3, extracted with DCM, and the organic phase was dried and then purified by rapid silica gel column chromatography to obtain 2.96 g of a pale yellow-green solid.
[0212] MS ESI: m / z = 154, [M+1] + .
[0213] Step 2: Preparation of M-2
[0214] M-1 (2000 mg) was dissolved in ultra-dry 1,4-dioxane (50 ml), and then methyl 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropanoate (2524 mg), Pd(OAc)2 (177.8 mg) were added. + BINAP (1329.7 mg) and Cs2CO3 (6937.2 mg) were added, and then the air was replaced with nitrogen and heated at 100° C. The reaction was completed after 3 h, quenched with saturated NH4Cl solution, extracted with EA, and the organic phase was spin-dried and then purified by rapid silica gel column chromatography to obtain 3.27 g of solid.
[0215] MS ESI: m / z = 315, [M+1] + .
[0216] Step 3: Preparation of M-3
[0217] M-2 (1000 mg) and NH 3 MeOH solution (7N) were added to a sealed tube, heated at 100° C. for 2 days, and then spin-dried and purified by flash silica gel column chromatography to obtain 900 mg of a light yellow solid.
[0218] MS ESI: m / z = 300, [M + 1] + .
[0219] Step 4: Preparation of T-1
[0220] M-3 (900 mg) was dissolved in ultra-dry THF (25 ml), and then Burgess reagent (1470 mg) was added. After stirring at room temperature for 3 h, the mixture was quenched with saturated NH4Cl solution, extracted with EA, and the organic phase was spin-dried and purified by flash silica gel column chromatography to obtain 440 mg of the product.
[0221] MS ESI: m / z = 282, [M+1] + .
[0222] 1 H NMR (400MHz, CDCl3) δ 8.67 (s, 1H), 8.21 (s, 1H), 7.57 (s, 1H), 6.76 (m, 1H), 6.73 (d, J = 2.0Hz, 1H), 2.31 (s, 3H), 2.02 (s, 6H).
[0223] Example 2: T-2
[0224] 2-Methyl-2-(3-methyl-4-((7-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-1H-pyrazol-1-yl)propionitrile
[0225]
[0226] T-1 (50 mg) was dissolved in DCM (4 ml) and ultrapure water (0.2 ml) under ice bath, and then CF3SO2Na (136.6 mg), tert-butyl hydroperoxide (0.27 ml, 5.5 N in decane) and DMSO (0.8 ml) were added. After stirring at 40 °C for 6 h, the reaction was completed, NH4Cl saturated solution was added to quench, EA was extracted, the organic phase was spin-dried and then purified by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 25 mg of solid T-2.
[0227] MS ESI: m / z = 350, [M+1] + .
[0228] 1 H NMR (400MHz, CDCl3) δ8.79 (s, 1H), 8.40 (s, 1H), 6.98 (d, J = 4.7Hz, 1H), 6.74 (d, J = 4.7Hz, 1H), 6.71 (s, 1H), 2.33 (s, 3H), 2.02 (s, 6H).
[0229] Example 3: T-3
[0230] 2-(4-((5-chloro-7-(trifluoromethyl)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0231]
[0232] T-2 (16 mg) was dissolved in ultra-dry DMF (3 ml), and NCS (5 mg) was added. After stirring for 3 h, NCS (3 mg) was added. After stirring overnight, the mixture was quenched with saturated NH4Cl solution, extracted with EA, and the organic phase was dried by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 3 mg of solid T-3.
[0233] MS ESI: m / z = 384, [M+1] + .
[0234] 1H NMR (400MHz, CDCl3) δ8.85(s,1H),8.34(s,1H),6.92(s,1H),6.59(s,1H),2.34(s,1H),2.01(s,3H).
[0235] Example 4: T-4
[0236] 2-(4-((5-chloro-7-methylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0237]
[0238] Step 1: Preparation of M-4
[0239] M-1 (1 g) was dissolved in acetonitrile (32 ml), and NBS (1159 mg) was added in an ice bath. After stirring in an ice bath for 2 h, the mixture was quenched with a saturated NH4Cl solution, extracted with EA, and the organic phase was spin-dried and purified by rapid silica gel column chromatography to obtain 1.2 g of solid M-4.
[0240] MS ESI: m / z = 232, [M+1] + .
[0241] Step 2: Preparation of M-5
[0242] M-4 (100 mg) was dissolved in 1,4-dioxane (4 ml) and water (0.4 ml), and then potassium methyl trifluoroborate (105 mg), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (70 mg) and cesium carbonate (421 mg) were added. After replacing the air with nitrogen, the mixture was stirred at 100°C overnight, quenched with NH4Cl saturated solution, extracted with EA, and the organic phase was spin-dried and then subjected to rapid silica gel column chromatography to obtain 30 mg of solid M-5.
[0243] MS ESI: m / z = 168, [M+1] + .
[0244] Step 3: Preparation of M-6
[0245] M-5 (30 mg) was dissolved in ultra-dry 1,4-dioxane (2 ml), and then 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile (29 mg), Pd(OAc)2 (12.2 mg), +BINAP (45.7 mg) and Cs2CO3 (95.6 mg). The air was then replaced with nitrogen, heated at 100°C overnight, quenched with saturated NH4Cl solution, extracted with EA, and the organic phase was spin-dried and purified by rapid silica gel column chromatography to obtain 19 mg of solid.
[0246] MS ESI: m / z = 296, [M+1] + .
[0247] Step 4: Preparation of T-4
[0248] M-6 (19 mg) was dissolved in DMF (2 ml), and NCS (8.5 mg) was added. After stirring at room temperature for 2 days, the mixture was quenched with saturated NH4Cl solution, extracted with EA, and the organic phase was dried by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 3.4 mg of solid T-4.
[0249] MS ESI: m / z = 330, [M+1] + .
[0250] 1 H NMR (400MHz, CDCl3) δ8.60(s,1H),8.33(s,1H),6.61(bs,1H),6.50(s,1H),2.53(s,3H),2.32(s,3H),2.00(s,6H).
[0251] Example 5: T-5
[0252] 2-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0253]
[0254] Step 1: Preparation of M-7
[0255] M-4 (100 mg) was dissolved in 1,4-dioxane (4 ml) and water (0.2 ml), and then cyclopropylboronic acid (92 mg), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium dichloromethane complex (70 mg) and potassium carbonate (178 mg) were added. After replacing the air with nitrogen, the mixture was stirred at 100 ° C for 3 h, quenched with NH4Cl saturated solution, extracted with EA, and the organic phase was spin-dried and then quickly chromatographed on a silica gel column to obtain 30 mg of solid M-5.
[0256] MS ESI: m / z = 194, [M+1] + .
[0257] Step 2: Preparation of M-8
[0258] Using M-7 (30 mg) as the raw material, 17 mg of M-8 was prepared under the same conditions as in the third step of Example 4.
[0259] MS ESI: m / z = 322, [M+1] + .
[0260] Step 3: Preparation of T-5
[0261] M-8 (17 mg) was dissolved in THF (1 ml) and MeOH (0.2 ml), and NCS (7 mg) was added. After stirring overnight, NCS (10 mg) was added. After stirring for 5 h, the reaction was completed and quenched with a saturated solution of NaHCO3. The organic phase was extracted with EA and dried by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 5.4 mg of solid T-5.
[0262] MS ESI: m / z = 356, [M+1] + .
[0263] 1 H NMR (400MHz, CDCl3) δ8.56(s,1H),8.40(s,1H),6.71(bs,1H),6.32(s,1H),2.33(s,3H),2.31–2.19(m,1H),1.99(s,6H),1.16(m,2H),0.89(m,2H).
[0264] Example 6: T-6
[0265] (±)-5-Chloro-N-(3-chloro-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazine-2-amine
[0266]
[0267] Step 1: Preparation of M-9
[0268] M-7 (50 mg) was dissolved in ultra-dry 1,4-dioxane (2 ml), and then 3-chloro-1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-amine (76.75 mg), Pd(OAc)2 (17.6 mg), + BINAP (65.9 mg) and Cs2CO3 (207 mg). The air was then replaced with nitrogen, heated at 100°C overnight, quenched with NH4Cl saturated solution, extracted with EA, and the organic phase was spin-dried and purified by rapid silica gel column chromatography to obtain 63 mg of M-9.
[0269] MS ESI: m / z = 436, [M+1] + .
[0270] Step 2: Preparation of T-6
[0271] M-9 (63 mg) was dissolved in THF (1.5 ml) and MeOH (0.5 ml), and NCS (17.4 mg) was added. After stirring for 6 h, the reaction was completed and quenched with a saturated solution of NaHCO3. The organic phase was extracted with EA and dried by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 25.7 mg of solid T-6.
[0272] MS ESI: m / z = 470, [M+1] + .
[0273] 1 H NMR (400MHz, CDCl3) δ8.56(s,1H),8.28(s,1H),6.63(bs,1H),6.26(s,1H),4.37(m,1H),3.96(m ,2H),2.99(m,2H),2.86(s,3H),2.39–2.24(m,3H),2.10(m,2H),1.17–1.06(m,2H),0.84(m,2H).
[0274] Example 7: T-7 and T-8
[0275] ±-trans-5-chloro-N-(3-chloro-1-(3-fluoro-1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazine-2-amine (T-7)
[0276] ±-trans-5,6-dichloro-N-(3-chloro-1-(3-fluoro-1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazine-2-amine (T-8)
[0277]
[0278] Step 1: Preparation of M-10
[0279] Dissolve cis-3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester (4 g) and 4-nitropyrazole in THF (90 ml), then add PPh3 (7.17 g) and DIAD (5.39 ml). After heating at 30 ° C for 7 hours, the reaction solution is filtered and dried, and then a light yellow oil is obtained by rapid silica gel column chromatography. It is dissolved in HCl 1,4-dioxane (40 ml, 4N) and stirred for 2 hours, and then dried to obtain M-10.
[0280] MS ESI: m / z = 215, [M+1] + .
[0281] Step 2: Preparation of M-11
[0282] DCM (10 ml), NEt3 (0.49 ml) and MsCl (0.27 ml) were added to the hydrochloride of M-10 (500 mg). After stirring for 1 h, the mixture was spin-dried and flash-chromatographed on a silica gel column to obtain 350 mg of M-11.
[0283] MS ESI: m / z = 293, [M+1] + .
[0284] Step 3: Preparation of M-12
[0285] M-11 (350 mg) was dissolved in ethanol (5 ml), and then palladium supported on alumina (70 mg, 5%), concentrated hydrochloric acid (0.86 ml) and triethylsilyl hydride (1.65 ml) were added. After stirring at room temperature for 1 day, triethylsilyl hydride (1.65 ml) was added, and after stirring overnight, the mixture was neutralized with NaHCO3 solution, extracted with EA, and dried by column to obtain 120 mg of M-12.
[0286] MS ESI: m / z = 297, [M+1] + .
[0287] Step 4: Preparation of M-13
[0288] Using M-7 (50 mg) and M-12 (81.7 mg) as raw materials, 41 mg of M-13 was prepared under the same conditions as in the first step of Example 6.
[0289] MS ESI: m / z = 454, [M+1] + .
[0290] Step 5: Preparation of T-7 and T-8
[0291] M-13 (41 mg) was dissolved in THF (1.5 ml) and MeOH (0.5 ml), and NCS (12 mg) was added. After stirring overnight, NCS (7 mg) was added and stirring was continued for 10 h. After the reaction was completed, the product was quenched with a saturated solution of NaHCO3 and extracted with EA. The organic phase was dried and purified by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave 18 mg of T-7 and 12 mg of T-8.
[0292] MS ESI: m / z = 488, [M+1] + (T-7).
[0293] 1 H NMR (400MHz, CDCl3) δ8.52(s,1H),8.30(s,1H),6.31(s,1H),5.10(m,1H),4.98(m,1H),4.45(m,1H),4.24(m, 1H),3.94(m,1H),3.03(m,2H),2.91(s,3H),2.48–2.26(m,1H),2.22–2.11(m,1H),1.18(m,2H),0.87(m,2H). (T-7)
[0294] MS ESI: m / z = 522, [M+1] + (T-8).
[0295] 1 H NMR (400MHz, CDCl3) δ8.57(s,1H),8.28(s,1H),6.54(s,1H),5.11(m,1H),5.05–4.94(m,1H),4.45(m,1H),4.36–4. 18(m,1H),3.95(m,1H),3.11–2.95(m,2H),2.92(s,3H),2.41(m,1H),2.13(m,1H),1.31(m,2H),1.19–1.01(m,2H). (T-8)
[0296] Examples 7A and 7B: Chiral separation of T-7-1 and T-7-2: T-7 was separated using a CHIRALPAK IG (Cat. No. IG00CE-AQ017) column with a flow rate of 0.8 ml / min and an eluent of 50% ethanol / n-hexane into Example 7A (T-7-1, 11.2 min) and Example 7B (T-7-2, 13.81 min).
[0297] Examples 7C and 7D: T-8-1 and T-8-2
[0298] Chiral separation: T-8 was separated using a CHIRALPAK IG (Cat. No. IG00CE-AQ017) column at a flow rate of 0.8 ml / min and an eluent of 50% ethanol / n-hexane to give Example 7C (T-8-1, 11.17 min) and Example 7D (T-8-2, 13.79 min).
[0299] Example 8: T-9
[0300] (±)-3-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile
[0301]
[0302] Using M-7 (50 mg) and (±)-3-(4-amino-3-methyl-1H-pyrazol-1-yl)cyclobutane-1-carbonitrile (55 mg) as raw materials, 47 mg of T-9 was prepared under the same conditions as in Example 6.
[0303] MS ESI: m / z = 368, [M+1] + .
[0304] 1 H NMR (400MHz, CDCl3) δ8.56(s,1H),8.09(s,1H),6.51(s,1H),6.28(s,1H),4.68(m, 1H),2.93(m,4H),2.85(m,1H),2.31(s,3H),2.25(m,1H),1.15(m,2H),0.91m,2H).
[0305] Examples 8A and 8B: Separation of cis and trans isomers of T-9-1 and T-9-2: T-9 was separated using a CHIRALPAK AD-H (Cat. No.: ADH0CE-EL100) column with a flow rate of 0.8 ml / min and an eluent of 50% ethanol / n-hexane to give Example 8A (T-9-1, 15.4 min) and Example 8B (T-9-2, 19.15 min).
[0306] Example 9: T-10
[0307] (±)-3-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-3-methyldihydrofuran-2(3H)-one
[0308]
[0309] Using M-7 (50 mg) and 3-(4-amino-3-methyl-1H-pyrazol-1-yl)-3-methyldihydrofuran-2(3H)-one (61 mg) as raw materials, 35 mg of T-10 was prepared under the same conditions as Example 6.
[0310] MS ESI: m / z = 387, [M+1] + .
[0311] 1 H NMR (400MHz, CDCl3) δ8.44(s,1H),8.31(s,1H),6.40(s,1H),4.55–4.34(m,2H),3.40–3.23(m, 1H),2.48(m,1H),2.35(s,3H),2.33–2.28(m,1H),1.79(s,3H),1.35–1.11(m,2H),0.95(s,2H).
[0312] Examples 9A and 9B: T-10-1 and T-10-2
[0313] Chiral separation: T-10 was separated into Example 9A (T-10-1, 11.27 min) and Example 9B (T-10-2, 14.95 min) using a CHIRALPAK AD-H (Cat. No. ADH0CE-EL100) column at a flow rate of 0.8 ml / min and an eluent of 50% ethanol / n-hexane.
[0314] Example 10: T-11
[0315] 2-((1-(2-cyanopropan-2-yl)-3-methyl-1H-pyrazol-4-yl)amino)-4-(methylamino)pyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile
[0316]
[0317] Step 1: Preparation of M-16
[0318] 2,4-Dichloropyrrolo[2,1-f][1,2,4]triazine (500 mg) was dissolved in iPrOH (20 ml), and methylamine hydrochloride (161.9 mg) and DIEA (0.76 ml) were added. After stirring for 2 h, water was added to quench the mixture, and then EA was used for extraction. The organic phase was dried by rotation to obtain 487 mg of M-16.
[0319] MS ESI: m / z = 183, [M+1] + .
[0320] Step 2: Preparation of M-18
[0321] M-16 (487 mg) was dissolved in DMF (10 ml), and NIS (493.65 mg) was added. After stirring for 3 h, the mixture was quenched with a saturated solution of NH4Cl, extracted with EA, and the organic phase was spin-dried and purified by rapid silica gel column chromatography to obtain 33 mg of M-18 and 656 mg of M-17.
[0322] MS ESI: m / z = 309, [M+1] + .
[0323] Step 3: Preparation of M-19
[0324] M-18 (33 mg) was dissolved in DMF (2 ml), and zinc cyanide (5.15 mg), Pd2dba3 (8 mg) and dppf (4.86 mg) were added. After replacing the air with nitrogen, the mixture was heated at 100°C for 4 h, and zinc cyanide (6 mg) was added. After heating for 1 h, the reaction was terminated, and the mixture was quenched with a saturated NH4Cl solution, extracted with EA, and the organic phase was spin-dried and subjected to rapid silica gel column chromatography to obtain 22 mg of M-19.
[0325] MS ESI: m / z = 208, [M+1] + .
[0326] Step 4: Preparation of T-11
[0327] Using M-19 (22 mg) and 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile (22 mg) as raw materials, 14.1 mg of T-11 was prepared under the same conditions as in the first step of Example 6.
[0328] MS ESI: m / z = 336, [M+1] + .
[0329] 1 H NMR (400MHz, CDCl3) δ8.11(s,1H),7.32(d,J=2.8Hz,1H),6.80(d,J=2.8Hz,1H ), 6.39 (s, 1H), 6.17 (s, 1H), 3.24 (d, J = 4.8Hz, 3H), 2.31 (s, 3H), 2.00 (s, 6H).
[0330] Example 11: T-12
[0331] 2-((1-(2-cyanopropan-2-yl)-3-methyl-1H-pyrazol-4-yl)amino)-7-cyclopropyl-4-(methylamino)pyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile
[0332]
[0333] Step 1: Preparation of M-20
[0334] Using M-16 (1.3 g) as the raw material, 1.74 g of M-20 was prepared under the same conditions as in the first step of Example 4.
[0335] MS ESI: m / z = 261, [M+1] + .
[0336] Step 2: Preparation of M-21
[0337] Using M-20 (1740 mg) as the raw material, 926 mg of M-21 was prepared under the same conditions as in the first step of Example 5.
[0338] MS ESI: m / z = 223, [M+1] + .
[0339] Step 3: Preparation of M-22
[0340] Using M-21 (200 mg) and 2-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile (163 mg) as raw materials, 182 mg of M-22 was prepared under the same conditions as in the first step of Example 6.
[0341] MS ESI: m / z = 336, [M+1] + .
[0342] Step 4: Preparation of M-23
[0343] Using M-22 (40 mg) as the starting material, 45 mg of M-23 was prepared under the same conditions as in the second step of Example 10.
[0344] MS ESI: m / z = 477, [M+1] + .
[0345] Step 5: Preparation of T-12
[0346] M-23 (45 mg) was dissolved in DMF (2 ml), and zinc cyanide (13.6 mg), Pd2dba3 (7 mg) and dppf (4 mg) were added. After replacing the air with nitrogen, the mixture was heated at 100 °C for 4 h, quenched with NH4Cl saturated solution, extracted with EA, and the organic phase was dried by rapid silica gel column chromatography and C 18 Reverse phase preparative chromatography gave T-12.
[0347] MS ESI: m / z = 376, [M+1] + .
[0348] 1H NMR (400MHz, CDCl3) δ8.37(s,1H),6.42(s,1H),6.11(s,1H),3.24(d,,3H),2.34(s,3H),2.14(m,1H),1.98(s,6H),1.10(m,2H),0.79(m,2H).
[0349] Example 12: T-13
[0350] 2-(4-((5-chloro-7-cyclopropyl-4-(methylamino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)-2-methylpropionitrile
[0351]
[0352] Using M-22 (40 mg) as the raw material, 18 mg of T-13 was prepared under the same conditions as in the second step of Example 6.
[0353] MS ESI: m / z = 385, [M+1] + .
[0354] 1 H NMR (400MHz, CDCl3) δ8.38(s,1H),6.17(s,1H),6.01(s,1H),5.96(s,1H),3. 13(s,3H),2.32(s,3H),2.16(m,1H),1.98(s,6H),1.04(m,2H),0.76(m,2H).
[0355] Example 13: T-14
[0356] (±)-(4-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)(cyclopropyl)methanone
[0357]
[0358] 72 mg of T-14 was prepared using M-7 (40 mg) and (4-(4-amino-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)(cyclopropyl)methanone (64 mg) under the same conditions as in Example 6.
[0359] MS ESI: m / z = 440, [M+1] + .
[0360] 1H NMR (400MHz, CDCl3) δ8.58(s,1H),8.02(s,1H),6.37(s,1H),6.26(s,1H),4.74(m,1H),4.30(m,2H),3.29(m,1H),2.80(m,1H ),2.30(s,3H),2.21(m,3H),1.98(m,2H),1.78(m,1H),1.13–1.04(m,2H),1.03–0.96(m,2H),0.92–0.84(m,2H),0.78(m,2H).
[0361] Example 14: T-15
[0362] (±)-1-(4-(4-((5-chloro-7-cyclopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl)amino)-3-methyl-1H-pyrazol-1-yl)piperidin-1-yl)-2,2-difluoropropan-1-one
[0363]
[0364] Step 1: Preparation of M-24
[0365] 4-(3-methyl-4-nitro-1H-pyrazol-1-yl)piperidine hydrochloride (202 mg) was dissolved in DCM (5 ml), and then HATU (501 mg), 2,2-difluoropropionic acid (190 mg) and DIEA (1.56 ml) were added. After reacting at room temperature for 3 h, the reaction solution was concentrated, diluted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and then subjected to column chromatography to obtain crude product M-24 (276 mg).
[0366] MS ESI: m / z = 303, [M+1] + .
[0367] Step 2: Preparation of M-25
[0368] M-24 (276 mg) was dissolved in methanol (10 ml), and then Pd / C (50 mg) was added. The mixture was stirred overnight under a hydrogen atmosphere, filtered, and dried by spin drying. Then, 148 mg of M-25 was obtained by flash silica gel column chromatography.
[0369] MS ESI: m / z = 273, [M+1] + .
[0370] Step 3: Preparation of M-26
[0371] Using M-7 (97 mg) and M-25 (148 mg) as raw materials, 25 mg of M-26 was prepared under the same conditions as in the first step of Example 6.
[0372] MS ESI: m / z = 430, [M+1] + .
[0373] Step 4: Preparation of T-15
[0374] Using M-26 (25 mg) as the raw material, 12 mg of T-15 was prepared under the same conditions as in the second step of Example 6.
[0375] MS ESI: m / z = 464, [M+1] + .
[0376] 1 H NMR (400MHz, CDCl3) δ8.57(s,1H),8.03(s,1H),6.37(s,1H),6.26(s,1H),4.62(m,1H),4.43(m,1H),4.37–4.26(m,1H),3.26(m,1H),2.9 2(m,1H),2.28(s,3H),2.25(m,1H),2.24–2.18(m,2H),2.04–1.97(m,2H),1.85(t,J=20.0Hz,3H),1.12–1.02(m,2H),0.92–0.82(m,2H).
[0377] LRRK2 activity inhibition assay
[0378] 1. Kinase reaction reagent formula
[0379] 1.1. Kinase reaction buffer (1X)
[0380] Table 1.1-1 ADP-Glo Buffer (LRRK2)
[0381] name Storage concentration Working concentration. Hepes 1M 50mM <![CDATA[MgCl2]]> 1M 10mM Brij35 30% 0.01% DTT 1M 2mM <![CDATA[H2O]]> N / A N / A EGTA N / A 1mM
[0382] 2mM DTT, prepared before use.
[0383] 1.2. Kinase formula
[0384] Table 1.2-1 Kinase formula
[0385]
[0386] 1.3. Substrate mixture formulation
[0387] Table 1.3-1 Substrate mixture formula
[0388] Kinase ATP concentration [μM] LRRK substrates LRRK2 20 0.1mg / mL
[0389] 2. Experimental Procedure
[0390] ADP-Glo method
[0391] 1) Prepare 2× ATP / substrate solution and 2× kinase / metal ion solution using kinase reaction buffer.
[0392] 2) Use Echo 655 to transfer 20 nL of compound dilution to the 384 assay plate; after centrifugation, add 2 μL of 2× kinase and metal ion solution to the 384 assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 10 minutes;
[0393] 3) Add 2 μL of 2× substrate and ATP solution to the 384 assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 60 minutes.
[0394] 4) Transfer 4 μL ADP-Glo to the 384 assay plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 40 minutes.
[0395] 5) Transfer 8 μL of the detection solution to a 384 detection plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 40 minutes.
[0396] 6) Read the luminescence signal using a multifunctional microplate reader.
[0397] 3. Data processing methods
[0398] The reading value of the negative control was set as 0% inhibition rate, and the reading value of the positive control was set as 100% inhibition rate, and the inhibition rate of each test solution was calculated.
[0399]
[0400] : Average value of positive control well ratio
[0401] : Average value of negative control well ratio
[0402] The IC of the compound was obtained using the following nonlinear fitting formula: 50 (half inhibitory concentration):
[0403] Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)*HillSlope))
[0404] X: log value of compound concentration
[0405] Y: Compound inhibition rate (%inh)
[0406] Z' factor calculation equation:
[0407] Z'=1-3(SDmin+SDmax) / (AVEmax-AVEmin)
[0408] in:
[0409] Min is the positive control Data value, and max is the negative control DMSO Data value.
[0410] SD is standard error and AVE is mean.
[0411] Table 2 LRRK2 activity inhibition test results
[0412]
[0413]
[0414] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt thereof, a stereoisomer thereof or a tautomer thereof, or a prodrug thereof: Where: Select from the following ring structures: Selected from the following bicyclic structures: in: X is selected from N or CR 5 ; R 1 , R 2 , R 4 , R 5 and R 6 Each independently is optionally replaced by one or more R s1 The substituted group is selected from the group consisting of hydrogen, halogen, amino, cyano, SF 5 , -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -C 0-6 Alkylene-OC 1-12 Alkyl, -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-4 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO 2 C 1-6 Alkyl, -C 0-6 Alkylene-SO 2 C 6-10 Aryl, -C 0-6 Alkylene-SO 2 5- to 10-membered heteroaryl, -C 0-6 Alkylene-SO 2 C 3-6 Cycloalkyl, -C 1-13 Alkylene -OH, -C 3-12 Cycloalkylene-OH; Each R s1 Independently selected from the group consisting of halogen, hydroxy, amino, cyano, C 1-6 Alkyl, -SO 2 NR a R b 、-SO 2 C 1-6 Alkyl, -SO 2 C 3-6 Cycloalkyl, -SO 2 C 6-10 Aryl, -SO 2 -5 to 10 membered heteroaryl, -CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a -5 to 10 membered heteroaryl, -COC 1-6 Alkyl, -COC 3-6 Cycloalkyl, -COC 6-10 Aryl, -CO-5 to 10 membered heteroaryl, C 1-6 Alkoxy and oxo (=O) radical substitution; R 3 is optionally represented by one or more R s2 The substituted group is selected from the group consisting of hydrogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -4 to 15 membered heterocyclic group, -C 0-6 Alkylene-OC 1-12 Alkyl, -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO 2 C 1-6 Alkyl, -C 0-6 Alkylene-SO 2 C 6-10 Aryl, -C 0-6 Alkylene-SO 2 5- to 10-membered heteroaryl, -C 0-6 Alkylene-SO 2 C 3-6 Cycloalkyl, -C 1-13 Alkylene -OH, -C 3-12 Cycloalkylene-OH; Each R s2 are independently optionally replaced by one or more R c or R 3a The substituted group is selected from the group consisting of halogen, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, OC 3-6 Cycloalkyl, amino, cyano, -SO 2 NR a R b 、-SO 2 R 8 、-CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a 5- to 10-membered heteroaryl, -C(O)R 8 and oxo; or, when two R s2 When located on adjacent atoms, they optionally together form a c The substituted ring is selected from the group consisting of: C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 Aryl and 5- to 10-membered heteroaryl; R 3a is optionally represented by one or more R s3 The substituted group is selected from the group consisting of hydrogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, -4 to 15 membered heterocyclic group, -C 0-6 Alkylene-OC 1-12 Alkyl, -C 1-12 Alkylthio, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, -C 0-6 Alkylene-C 6-10 Aryl, -C 0-6 Alkylene-5 to 10 membered heteroaryl, -C 0-6 Alkylene-C(O)R a , -C 0-6 Alkylene-C(O)OR a , -C 0-6 Alkylene-C(O)NR a R b , -C 0-6 Alkylene-SO 2 C 1-6 Alkyl, -C 0-6 Alkylene-SO 2 C 6-10 Aryl, -C 0-6 Alkylene-SO 2 5- to 10-membered heteroaryl, -C 0-6 Alkylene-SO 2 C 3-6 Cycloalkyl, -C 1-12 Alkylene -OH, -C 3-12 Cycloalkylene-OH; Each R s3 Independently selected from the group consisting of halogen, hydroxyl, C 1-6 Alkyl, -OC 1-6 Alkyl, C 1-6 Haloalkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl, -C 0-6 Alkylene-3 to 10 membered heterocyclic group, OC 3-6 Cycloalkyl, amino, cyano, -SO 2 NR a R b 、-SO 2 R 8 、-CONR a R b 、-CONR a -C 6-10 Aryl, -CONR a 5- to 10-membered heteroaryl, -C(O)R 8 and oxo-group substitution; Or, when R 1 and R 2 , R 1 and R 3 or R 2 and R 3 When located on adjacent atoms, R 1 and R 2 , R 1 and R 3 or R 2 and R 3 optionally together form optionally one or more R c The substituted ring is selected from the group consisting of: C 3-10 Cycloalkyl, 3- to 10-membered heterocyclic group, C 6-10 Aryl and 5- to 10-membered heteroaryl; R 7 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, NR a R b , OR a ; R 8 is optionally represented by one or more R c The substituted group is selected from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, C 6-10 Aryl, 5- to 10-membered heteroaryl; R a and R b Independently selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, or R a and R b Together with the nitrogen atom to which they are attached, they optionally form a 3- to 6-membered heterocyclic ring wherein the heteroatoms are selected from N, O and S; R c Each independently selected from the group consisting of halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl, -NH 2 、-CN、-NH(C 1-4 Alkyl), -N(C 1-4 alkyl) 2 、-OH、-OC 1-6 Alkyl; or, when both R c When located on the same atom, they are optionally together formed unsubstituted or substituted with one or more selected from halogen, -CN and C 1-4 The C substituted by the alkyl substituent 3-6 Cycloalkyl.
2. The compound according to claim 1, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that The compound has a structure represented by a general formula selected from the following group: Wherein, Y is selected from S, O, NR 2 ; The definitions of other groups are as described in claim 1.
3. The compound according to claim 1, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that Have one or more of the following characteristics: (a)R 1 Selected from the group consisting of hydrogen, cyano, halogen, -C 1-12 Alkyl, -C 2-12 Alkenyl, -C 2-12 Alkynyl, C 3-10 Cycloalkyl; (b)R 2 Selected from the group consisting of hydrogen, -C 1-12 alkyl; (c)R 4 , R 5 and R 6 Each independently is one or more R s1 The substituted group is selected from the group consisting of hydrogen, halogen, -C 1-12 Alkyl, -C 0-6 Alkylene-C 3-10 Cycloalkyl; wherein each R s1 Independently selected from the group consisting of halogen, C 1-6 alkyl; (d) R 7 Selected from the group consisting of hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 3-6 Halogenated cycloalkyl.
4. The compound according to claim 1, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that R 3 Select from the following group: -C(C 1-6 alkyl) 2 -R s2 , in, Y 1 Select from the following group: CH 2 , CHR s2 , C(R s2 ) 2 , O, S, SO, SO 2 , NH, NR s2 ; n3 and n6 are each independently 0, 1, 2 or 3; n1 and n2 are each independently 0, 1, 2 or 3, and n1 and n2 are not 0 or 3 at the same time; n4 and n5 are each independently 0, 1 or 2, and n4 and n5 are not 0 at the same time; n7 and n8 are each independently 1 or 2; n9 and n10 are each independently 0 or 1; R s2 As defined in Formula I.
5. The compound according to claim 1, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that The compound is selected from Table A or selected from Example compounds T-1, T-2, T-3, T-4, T-5, T-6, T-7, T-8, T-9, T-10, T-11, T-12, T-13 and T-14.
6. A pharmaceutical composition, It is characterized in that The invention comprises (a) a safe and effective amount of an active ingredient of a compound as claimed in any one of claims 1 to 5 or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, and (b) a pharmaceutically acceptable carrier or excipient.
7. Use of a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, a stereoisomer or a tautomer thereof, or a prodrug thereof, It is characterized in that The use is selected from one or more of the following groups: (i) preparing LRRK2 inhibitors; (ii) preparing a drug for treating or preventing a disease mediated by LRRK2; (iii) preparing drugs for treating or preventing Parkinson's disease and cancer; (iv) preparing a drug for treating or preventing cancer in combination with an immune checkpoint protein inhibitor; (v) preparing drugs for treating or preventing inflammatory diseases, tumors and / or neurodegenerative diseases; (vi) preparing a drug for treating or preventing tumors for use in combination with a tumor drug or therapy.
8. The use according to claim 7, It is characterized in that The LRRK2-mediated disease is selected from the group consisting of tumors, neurodegenerative diseases, and inflammatory diseases.
9. The use according to claim 7, It is characterized in that The LRRK2-mediated disease is selected from the group consisting of cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel disease (IBD), tuberculosis, leprosy, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, atopic dermatitis, rheumatoid arthritis, spondyloarthritis, gout, systemic lupus erythematosus, Sjögren's syndrome, systemic scleroderma, antiphospholipid syndrome, vasculitis, osteoarthritis, nonalcoholic fatty liver hepatitis, autoimmune hepatitis, autoimmune Epidemic hepatobiliary diseases, primary sclerocholangitis, nephritis, celiac disease, autoimmune ITP, transplant rejection, ischemia-reperfusion injury of solid organs, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington's disease, allergic diseases, asthma, multiple sclerosis, type 2 diabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-1 converting enzyme-associated febrile syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated periodic syndrome and periodontitis.
10. A drug combination, It is characterized in that The pharmaceutical composition comprises: (a) a first active ingredient, wherein the first active ingredient is a compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, a stereoisomer or a tautomer thereof, or a prodrug thereof; and (b) a second active ingredient, wherein the second active ingredient is an immune checkpoint protein inhibitor.
